Skip to main content
. 2016 Jun 3;82(3):773–783. doi: 10.1111/bcp.12989

Table 3.

Parameter estimate for the pharmacodynamic model of NT‐proBNP

Parameter (unit) Estimate (RSE) [Shrinkage] Bootstrap median [95% CI]
kin_0 (ng⋅ml−1 h−1) 110 (13%) 102 (73, 144)
kout (h−1) * 1.66 (−)
β (l⋅μg−1) 115 (22%) 98 (47, 166)
MTT (h) 34.7 (12%) 42 (30, 52)
BSV
BSV‐kin_0 (% CV) 48.5 (22%) [8%] 51.6 (11.8, 87.1)
BSV‐β (% CV) 73.9 (21%) [8%] 83.5 (37.0, 144)
BSV‐MTT (% CV) 38.8 (34%) [8%] 34.8 (2.4, 61.1)
IOV
IOV‐kin_0 (% CV) 27.8 (17%) [27%] 26.9 (18.4, 38.6)
RUV
RUV‐BNP (% CV) 23.8 (15.2%) [23%] 23.6 (17.0, 32.3)
*

this parameter was fixed to literature value. β, slope factor as defined in Equation (3). BSV, between‐subject variability; CI, confidence interval; CV%, coefficient of variation; IOV, interoccasion variability; kin_0, baseline production rate of NT‐proBNP; kout, degradation rate constant of NT‐proBNP synthesis pathway; MTT, mean transit time; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; RUV, random unexplained variability;. Shrinkage of BSV, IOV and RUV is presented in square brackets.